For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$11.27
Thesis
Telix Pharmaceuticals is a commercial radiopharmaceutical company built on an approved prostate cancer imaging agent. Diagnostic revenue funds a broadening therapeutic radioligand pipeline across oncology.
Catalysts
- Illuccix commercial growth
- Kidney and additional diagnostic approvals
- Therapeutic radioligand program advancement
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Sep 21PartnershipSEC
Telix Pharmaceuticals files 6-K on collaboration with ITM.
- Sep 14RegulatorySEC
Telix Pharmaceuticals 6-K reports FDA approval of Pixclara.
- Sep 2Trial initiationSEC
6-K filing on Phase 3 BIPASS trial enrollment update.
- Sep 1LeadershipSEC
6-K reports appointment of David at Telix Pharmaceuticals Limited.
- Aug 20Financial resultsSEC
Telix Pharmaceuticals files 6-K report covering period ended June 30, 2026.
- Jul 21Financial resultsSEC
6-K filing containing Q2 2026 trading update for foreign issuer.
- Jul 2Trial initiationSEC
Telix Pharmaceuticals filed Form 6-K covering ProstACT GLOBAL P trial update.
- May 27Trial initiationClinicalTrials.gov
Phase 3 ProstACT Global trial (NCT06520345) of 177Lu-TLX591 + SOC vs SOC in mCRPC now recruiting